Mechanisms for progenitor cell-mediated repair for Ischemic Heart Injury

Current Stem Cell Research and Therapy

Volumn 7, Issue 1, 2012, Pages 2-14

  Li, Shengwen Calvin ^a,b   Acevedo, Julyana ^a,b,h   Wang, Lang ^d   Jiang, Hong ^d   Luo, Jane ^e   Pestell, Richard G ^g   Loudon, William G ^a,f   Chang, Anthony C ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

^c CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^d WUHAN UNIVERSITY   (China)

^e BECKMAN COULTER INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cardiac infarction; Cell based cardiac therapy; Heart injury; Precursor cells; Stem cells

Indexed keywords

ANGIOPOIETIN 1; C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CELL HOMING; CELL MIGRATION; CELL PROTECTION; CELL SURVIVAL; CELL TRANSDIFFERENTIATION; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; ENDOTHELIAL PROGENITOR CELL; HEART FAILURE; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOXIA; MESENCHYMAL STEM CELL; NONHUMAN; PARACRINE SIGNALING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; STEM CELL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE REPAIR;

EID: 84862962164     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488812798483449     Document Type: Review

References (177)

1. He Q, Trindade PT, Stumm M, et al. Fate of undifferentiated mouse embryonic stem cells within the rat heart: role of myocardial infarction and immune suppression. J Cell Mol Med 2009; 13(1): 188-201.
2. Nussbaum J, Minami E, Laflamme MA, et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. Faseb J 2007; 21(7): 1345-57.
3. Bartunek J, Dimmeler S, Drexler H, et al. The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart. Eur Heart J 2006; 27(11): 1338-40.
4. Odorfer KI, Walter I, Kleiter M, Sandgren EP, Erben RG. Role of endogenous bone marrow cells in long-term repair mechanisms after myocardial infarction. J Cell Mol Med 2008; 12(6B): 2867-74.
5. Trop S, Tremblay ML, Bourdeau A. Modulation of bone marrowderived endothelial progenitor cell activity by protein tyrosine phosphatases. Trends Cardiovasc Med 2008; 18(5): 180-6.
6. Kudo M, Wang Y, Wani MA, Xu M, Ayub A, Ashraf M. Implantation of bone marrow stem cells reduces the infarction and fibrosis in ischemic mouse heart. J Mol Cell Cardiol 2003; 35(9): 1113-9.
7. Lasala GP, Minguell JJ. Bone marrow-derived stem/progenitor cells: their use in clinical studies for the treatment of myocardial infarction. Heart Lung Circ 2009; 18(3): 171-80.
8. Potier E, Ferreira E, Meunier A, Sedel L, Logeart-Avramoglou D, Petite H. Prolonged hypoxia concomitant with serum deprivation induces massive human mesenchymal stem cell death. Tissue Eng 2007; 13(6): 1325-31.
9. Berry MF, Engler AJ, Woo YJ, et al. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol 2006; 290(6): H2196-203.
10. Nagaya N, Kangawa K, Itoh T, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005; 112(8): 1128-35.
11. Li SC, Wang L, Jiang H, Acevedo J, Chang AC, Loudon WG. Stem cell engineering for treatment of heart diseases: Potentials and challenges. Cell Biol Int 2009; 33(3): 255-67.
12. Guzun R, Timohhina N, Tepp K, et al. Regulation of respiration controlled by mitochondrial creatine kinase in permeabilized cardiac cells in situ. Importance of system level properties. Biochim Biophys Acta 2009; 1787(9): 1089-105.
13. Ernens I, Goodfellow SJ, Innes F, et al. Hypoxic stress suppresses RNA polymerase III recruitment and tRNA gene transcription in cardiomyocytes. Nucleic Acids Res 2006; 34(1): 286-94.
14. Bekedam MA, van Beek-Harmsen BJ, van Mechelen W, Boonstra A, Visser FC, van der Laarse WJ. Sarcoplasmic reticulum ATPase activity in type I and II skeletal muscle fibres of chronic heart failure patients. Int J Cardiol 2009; 133(2): 185-90.
15. Yuan Z, Cai T, Tian J, Ivanov AV, Giovannucci DR, Xie Z. Na/KATPase tethers phospholipase C and IP3 receptor into a calciumregulatory complex. Mol Biol Cell 2005; 16(9): 4034-45.
16. Lin L, Cui L, Zhou W, et al. Beta-catenin directly regulates Islet1 expression in cardiovascular progenitors and is required for multiple aspects of cardiogenesis. Proc Natl Acad Sci USA 2007; 104(22): 9313-8.
17. Wang GW, Klein JB, Kang YJ. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J Pharmacol Exp Ther 2001; 298(2): 461-8.
18. Waetzig GH, Rosenstiel P, Arlt A, et al. Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1. Faseb J 2005; 19(1): 91-3.
19. Bonetti A, Marchini M, Ortolani F. Immunolocalization of interleukin-1 receptor antagonist in healthy and infarcted myocardium. Histol Histopathol 2008; 23(9): 1093-102.
20. Harder Y, Amon M, Schramm R, et al. Erythropoietin reduces necrosis in critically ischemic myocutaneous tissue by protecting nutritive perfusion in a dose-dependent manner. Surgery 2009; 145(4): 372-83.
21. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VW. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res 2009; 335(1): 165-89.
22. Lv X, Wan J, Yang J, et al. Cytochrome P450 omega-hydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 signaling in rat myocardial ischemia-reperfusion. Eur J Pharmacol 2008; 596(1-3): 118-26.
23. Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. Embo J 2000; 19(23): 6341-50.
24. Talmor D, Applebaum A, Rudich A, Shapira Y, Tirosh A. Activation of mitogen-activated protein kinases in human heart during cardiopulmonary bypass. Circ Res 2000; 86(9): 1004-7.
25. Duplain H. Salvage of ischemic myocardium: a focus on JNK. Adv Exp Med Biol 2006; 588: 157-64.
26. Ferrandi C, Ballerio R, Gaillard P, et al. Inhibition of c-Jun Nterminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats. Br J Pharmacol 2004; 142(6): 953-60.
27. He H, Li HL, Lin A, Gottlieb RA. Activation of the JNK pathway is important for cardiomyocyte death in response to simulated ischemia. Cell Death Differ 1999; 6(10): 987-91.
28. Shao Z, Bhattacharya K, Hsich E, et al. c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. Circ Res 2006; 98(1): 111-8.
29. Yang LM, Xiao YL, Ou-Yang JH. [Inhibition of magnesium lithospermate B on the c-Jun N-terminal kinase 3 mRNA expression in cardiomyocytes encountered ischemia/reperfusion injury]. Yao Xue Xue Bao 2003; 38(7): 487-91.
30. Yoshinari D, Takeyoshi I, Kobayashi M, et al. Effects of a p38 mitogen-activated protein kinase inhibitor as an additive to university of wisconsin solution on reperfusion injury in liver transplantation. Transplantation 2001; 72(1): 22-7.
31. Iacobas DA, Fan C, Iacobas S, Haddad GG. Integrated transcriptomic response to cardiac chronic hypoxia: translation regulators and response to stress in cell survival. Funct Integr Genomics 2008; 8(3): 265-75.
32. Brehm M, Stanske B, Strauer BE. Therapeutic potential of stem cells in elderly patients with cardiovascular disease. Exp Gerontol 2008; 43(11): 1024-32.
33. Krupnick AS, Kreisel D, Riha M, Balsara KR, Rosengard BR. Myocardial tissue engineering and regeneration as a therapeutic alternative to transplantation. Curr Top Microbiol Immunol 2004; 280: 139-64.
34. Yu Y, Fukuda N, Yao EH, et al. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am J Hypertens 2008; 21(1): 72-7.
35. Boudoulas KD, Hatzopoulos AK. Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease. Dis Model Mech 2009; 2(7-8): 344-58.
36. LaPar DJ, Kron IL, Yang Z. Stem cell therapy for ischemic heart disease: where are we? Curr Opin Organ Transplant 2009; 14(1): 79-84.
37. Seidel M, Borczynnska A, Rozwadowska N, Kurpisz M. Cellbased therapy for heart failure: skeletal myoblasts. Cell Transplant 2009; 18(7): 695-707.
38. Yamada S, Nelson TJ, Behfar A, Crespo-Diaz RJ, Fraidenraich D, Terzic A. Stem cell transplant into preimplantation embryo yields myocardial infarction-resistant adult phenotype. Stem Cells 2009; 27(7): 1697-705.
39. Kim HW, Haider HK, Jiang S, Ashraf M. Ischemic preconditioning augments survival of stem cells via MIR-210 expression by targeting caspase-8 associated protein 2. J Biol Chem 2009; 284(48): 33161-8.
40. Wisel S, Khan M, Kuppusamy ML, et al. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther 2009; 329(2): 543-50.
41. Valen G. Extracardiac approaches to protecting the heart. Eur J Cardiothorac Surg 2009; 35(4): 651-7.
42. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008; 88(2): 581-609.
43. Cavero I, Djellas Y, Guillon JM. Ischemic myocardial cell protection conferred by the opening of ATP-sensitive potassium channels. Cardiovasc Drugs Ther 1995; 9(Suppl 2): 245-55.
44. Shu J, Ren N, Du JB, Zhang M, Cong HL, Huang TG. Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome. Scand Cardiovasc J 2007; 41(3): 149-54.
45. Vinten-Johansen J, Zhao ZQ, Nakamura M, et al. Nitric oxide and the vascular endothelium in myocardial ischemia-reperfusion injury. Ann N Y Acad Sci 1999; 874: 354-70.
46. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296(5573): 1634-5.
47. Yang YY, Liu H, Nam SW, Kunos G, Lee SS. Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile ductligated mice: interaction between TNFalpha and endocannabinoids. J Hepatol 2011; 53(2): 298-306.
48. Hu Y, Chen X, Pan TT, et al. Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways. Pflugers Arch 2008; 455(4): 607-16.
49. Rosova I, Dao M, Capoccia B, Link D, Nolta JA. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008; 26(8): 2173-82.
50. Li SC, Han YP, Dethlefs BA, Loudon WG. Therapeutic Window, a Critical Developmental Stage for Stem Cell Therapies. Curr Stem Cell Res Ther 2010; 5(4): 297-3.
51. Zhang FB, Yang HT. [Plasticity of bone marrow mesenchymal stem cells differentiating into cardiomyocytes and the potential of cardiac therapeutics]. Sheng Li Ke Xue Jin Zhan 2006; 37(3): 199-204.
52. Zhang S, Ge J, Sun A, et al. Comparison of various kinds of bone marrow stem cells for the repair of infarcted myocardium: single clonally purified non-hematopoietic mesenchymal stem cells serve as a superior source. J Cell Biochem 2006; 99(4): 1132-47.
53. Bartunek J, Dimmeler S, Drexler H, et al. The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart. Eur Heart J 2006; 27(11): 1338-40.
54. Papathanasopoulos A, Giannoudis PV. Biological considerations of mesenchymal stem cells and endothelial progenitor cells. Injury 2008; 39(Suppl 2): S21-32.
55. Roche S, Provansal M, Tiers L, Jorgensen C, Lehmann S. Proteomics of primary mesenchymal stem cells. Regen Med 2006; 1(4): 511-7.
56. Iop L, Chiavegato A, Callegari A, et al. Different cardiovascular potential of adult-and fetal-type mesenchymal stem cells in a rat model of heart cryoinjury. Cell Transplant 2008; 17(6): 679-94.
57. Balana B, Nicoletti C, Zahanich I, et al. 5-Azacytidine induces changes in electrophysiological properties of human mesenchymal stem cells. Cell Res 2006; 16(12): 949-60.
58. Heubach JF, Graf EM, Leutheuser J, et al. Electrophysiological properties of human mesenchymal stem cells. J Physiol 2004; 554(Pt 3): 659-72.
59. Bonnet P, Awede B, Rochefort GY, et al. Electrophysiological maturation of rat mesenchymal stem cells after induction of vascular smooth muscle cell differentiation in vitro. Stem Cells Dev 2008; 17(6): 1131-40.
60. Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008; 3(4): e1886.
61. Luttun A, Carmeliet P. De novo vasculogenesis in the heart. Cardiovasc Res 2003; 58(2): 378-89.
62. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol 2008; 51(6): 660-8.
63. Carrancio S, Lopez-Holgado N, Sanchez-Guijo FM, et al. Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification. Exp Hematol 2008; 36(8): 1014-21.
64. Molina EJ, Gupta D, Palma J, Gaughan JP, Macha M. Right ventricular beneficial effects of beta adrenergic receptor kinase inhibitor (betaARKct) gene transfer in a rat model of severe pressure overload. Biomed Pharmacother 2009; 63(5): 331-6.
65. Molina EJ, Palma J, Gupta D, Gaughan JP, Houser S, Macha M. Right ventricular effects of intracoronary delivery of mesenchymal stem cells (MSC) in an animal model of pressure overload heart failure. Biomed Pharmacother 2009; 63(10): 767-72.
66. Molina EJ, Palma J, Gupta D, et al. Reverse remodeling is associated with changes in extracellular matrix proteases and tissue inhibitors after mesenchymal stem cell (MSC) treatment of pressure overload hypertrophy. J Tissue Eng Regen Med 2009; 3(2): 85-91.
67. Christoforou N, Gearhart JD. Stem cells and their potential in cellbased cardiac therapies. Prog Cardiovasc Dis 2007; 49(6): 396-413.
68. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103(23): 2776-9.
69. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 2006; 66(18): 9054-64.
70. Ceradini DJ, Gurtner GC. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 2005; 15(2): 57-63.
71. Hu X, Dai S, Wu WJ, et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation 2007; 116(6): 654-63.
72. Lima e Silva R, Shen J, Hackett SF, et al. The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. Faseb J 2007; 21(12): 3219-30.
73. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28(7): 299-307.
74. Hoenig MR, Bianchi C, Sellke FW. Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis. Curr Drug Targets 2008; 9(5): 422-35.
75. Ju SY, Cho KA, Cho SJ, et al. Effect of hypoxic treatment on bone marrow cells that are able to migrate to the injured liver. Cell Biol Int 2009; 33(1): 31-5.
76. Kubo M, Li TS, Kamota T, Ohshima M, Qin SL, Hamano K. Increased expression of CXCR4 and integrin alphaM in hypoxiapreconditioned cells contributes to improved cell retention and angiogenic potency. J Cell Physiol 2009; 220(2): 508-14.
77. Li N, Lu X, Zhao X, et al. Endothelial nitric oxide synthase promotes bone marrow stromal cell migration to the ischemic myocardium via upregulation of stromal cell-derived factor-1alpha. Stem Cells 2009; 27(4): 961-70.
78. Lin JS, Chen YS, Chiang HS, Ma MC. Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: role of erythropoietin on progenitor cell mobilization. J Physiol 2008; 586(Pt 23): 5757-69.
79. Tang YL, Zhu W, Cheng M, et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 2009; 104(10): 1209-16.
80. Wang X, Li C, Chen Y, et al. Hypoxia enhances CXCR4 expression favoring microglia migration via HIF-1alpha activation. Biochem Biophys Res Commun 2008; 371(2): 283-8.
81. Zagzag D, Esencay M, Mendez O, et al. Hypoxia-and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol 2008; 173(2): 545-60.
82. Shi M, Li J, Liao L, et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica 2007; 92(7): 897-904.
83. Kyriakou C, Rabin N, Pizzey A, Nathwani A, Yong K. Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model. Haematologica. 2008; 93(10): 1457-65.
84. Venkatesan S, Rose JJ, Lodge R, Murphy PM, Foley JF. Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. MolBiolCell 2003; 14(8): 3305-24.
85. Hur J, Yoon CH, Lee CS, et al. Akt is a key modulator of endothelial progenitor cell trafficking in ischemic muscle. Stem Cells 2007; 25(7): 1769-78.
86. Schroeter MR, Leifheit M, Sudholt P, et al. Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrin-mediated adhesion. Circ Res 2008; 103(5): 536-44.
87. Rezai N, Deisher TA, Heine HL, et al. Effects of granulocytecolony stimulating factor on bone marrow-derived progenitor cells in murine cardiac transplantation. Cardiovasc Pathol 2010; 19(1): 36-47.
88. Tatsumi K, Otani H, Sato D, et al. Granulocyte-colony stimulating factor increases donor mesenchymal stem cells in bone marrow and their mobilization into peripheral circulation but does not repair dystrophic heart after bone marrow transplantation. Circ J 2008; 72(8): 1351-8.
89. Pallante BA, Duignan I, Okin D, et al. Bone marrow Oct3/4+ cells differentiate into cardiac myocytes via age-dependent paracrine mechanisms. Circ Res 2007; 100(1): e1-11.
90. Xie XJ, Wang JA, Cao J, Zhang X. Differentiation of bone marrow mesenchymal stem cells induced by myocardial medium under hypoxic conditions. Acta Pharmacol Sin 2006; 27(9): 1153-8.
91. Zhang Z, Deb A, Zhang Z, et al. Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. J Mol Cell Cardiol 2009; 46(3): 370-7.
92. Schumann H, Holtz J, Zerkowski HR, Hatzfeld M. Expression of secreted frizzled related proteins 3 and 4 in human ventricular myocardium correlates with apoptosis related gene expression. Cardiovasc Res 2000; 45(3): 720-8.
93. Shujia J, Haider HK, Idris NM, Lu G, Ashraf M. Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovasc Res 2008; 77(3): 525-33.
94. Koyanagi M, Bushoven P, Iwasaki M, Urbich C, Zeiher AM, Dimmeler S. Notch signaling contributes to the expression of cardiac markers in human circulating progenitor cells. Circ Res 2007; 101(11): 1139-45.
95. Wei HJ, Chen CH, Lee WY, et al. Bioengineered cardiac patch constructed from multilayered mesenchymal stem cells for myocardial repair. Biomaterials 2008; 29(26): 3547-56.
96. Shi RZ, Wang JC, Huang SH, Wang XJ, Li QP. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp Cell Res 2009; 315(1): 10-5.
97. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. Faseb J 2006; 20(6): 661-9.
98. Ishibe S, Joly D, Zhu X, Cantley LG. Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factorstimulated epithelial morphogenesis. Mol Cell 2003; 12(5): 1275-85.
99. Wen Y, Zhang XJ, Ma YX, Xu XJ, Hong LF, Lu ZH. Erythropoietin attenuates hypertrophy of neonatal rat cardiac myocytes induced by angiotensin-II in vitro. Scand J Clin Lab Invest 2009; 69(4): 518-25.
100. Lorenz K, Schmitt JP, Schmitteckert EM, Lohse MJ. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 2009; 15(1): 75-83.
101. Liu XH, Bai CG, Xu ZY, et al. Therapeutic potential of angiogenin modified mesenchymal stem cells: angiogenin improves mesenchymal stem cells survival under hypoxia and enhances vasculogenesis in myocardial infarction. Microvasc Res 2008; 76(1): 23-30.
102. Li SC, Loudon WG. Stem Cell Therapy for Paediatric Malignant Brain Tumours: The Silver Bullet? ONcology News (UK), June-July 2008, ISSN 1751-4975, 2008; 3(1): 10-4. http://www.oncologynews.biz/pdf/jun_jul_08/ONJJ_stemcell.pdf (Accessed May 4, 2008).
103. Hagikura K, Fukuda N, Yokoyama SI, et al. Low invasive angiogenic therapy for myocardial infarction by retrograde transplantation of mononuclear cells expressing the VEGF gene. Int J Cardiol 2010; 142(1): 56-64.
104. Guo J, Lin GS, Bao CY, Hu ZM, Hu MY. Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction. Inflammation 2007; 30(3-4): 97-104.
105. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemiareperfusion injury in mouse heart. Circulation 2000; 101(6): 660-7.
106. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem 2003; 278(41): 39422-7.
107. Shiojima I, Yefremashvili M, Luo Z, et al. Akt signaling mediates postnatal heart growth in response to insulin and nutritional status. J Biol Chem 2002; 277(40): 37670-7.
108. Taniyama Y, Walsh K. Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. J Mol Cell Cardiol 2002; 34(10): 1241-7.
109. Chimenti I, Smith RR, Li TS, et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res 2011; 106(5): 971-80.
110. Lee ST, White AJ, Matsushita S, et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol 2011; 57(4): 455-65.
111. Mazo M, Pelacho B, Prosper F. Stem cell therapy for chronic myocardial infarction. J Cardiovasc Transl Res 2011; 3(2): 79-88.
112. Noort WA, Feye D, Van Den Akker F, et al. Mesenchymal stromal cells to treat cardiovascular disease: strategies to improve survival and therapeutic results. Panminerva medica 2011; 52(1): 27-40.
113. Soejitno A, Wihandani DM, Kuswardhani RA. Clinical applications of stem cell therapy for regenerating the heart. Acta medica Indonesiana 2011; 42(4): 243-57.
114. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail 2011; 12(7): 721-9.
115. Bironaite D, Baltriukiene D, Uralova N, et al. Role of MAP kinases in nitric oxide induced muscle-derived adult stem cell apoptosis. Cell Biol Int 2009; 33(7): 711-9.
116. Jaquet K, Krause KT, Denschel J, et al. Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism? Stem Cells Dev 2005; 14(3): 299-309.
117. Li H, Yu B, Zhang Y, Pan Z, Xu W, Li H. Jagged1 protein enhances the differentiation of mesenchymal stem cells into cardiomyocytes. Biochem Biophys Res Commun 2006; 341(2): 320-5.
118. Tang J, Xie Q, Pan G, Wang J, Wang M. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg 2006; 30(2): 353-61.
119. Tokcaer-Keskin Z, Akar AR, Ayaloglu-Butun F, et al. Timing of induction of cardiomyocyte differentiation for in vitro cultured mesenchymal stem cells: a perspective for emergencies. Can J Physiol Pharmacol 2009; 87(2): 143-50.
120. Wang T, Xu Z, Jiang W, Ma A. Cell-to-cell contact induces mesenchymal stem cell to differentiate into cardiomyocyte and smooth muscle cell. Int J Cardiol 2006; 109(1): 74-81.
121. Xu W, Zhang X, Qian H, et al. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med (Maywood) 2004; 229(7): 623-31.
122. Plotnikov EY, Khryapenkova TG, Vasileva AK, et al. Cell-to-cell cross-talk between mesenchymal stem cells and cardiomyocytes in co-culture. J Cell Mol Med 2008; 12(5A): 1622-31.
123. Derval N, Barandon L, Dufourcq P, et al. Epicardial deposition of endothelial progenitor and mesenchymal stem cells in a coated muscle patch after myocardial infarction in a murine model. Eur J Cardiothorac Surg 2008; 34(2): 248-54.
124. Arminan A, Gandia C, Bartual M, et al. Cardiac differentiation is driven by NKX2.5 and GATA4 nuclear translocation in tissuespecific mesenchymal stem cells. Stem Cells Dev 2009; 18(6): 907-18.
125. Luiken JJ, Ouwens DM, Habets DD, et al. Permissive action of protein kinase C-zeta in insulin-induced CD36-and GLUT4 translocation in cardiac myocytes. J Endocrinol 2009; 201(2): 199-209.
126. Lian F, Xue S, Gu P, Zhu HS. The long-term effect of autologous endothelial progenitor cells from peripheral blood implantation on infarcted myocardial contractile force. J Int Med Res 2008; 36(1): 40-6.
127. Muscari C, Bonafe F, Carboni M, et al. Difluoromethylornithine stimulates early cardiac commitment of mesenchymal stem cells in a model of mixed culture with cardiomyocytes. J Cell Biochem 2008; 103(4): 1046-52.
128. Behfar A, Perez-Terzic C, Faustino RS, et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med 2007; 204(2): 405-20.
129. Koyanagi M, Brandes RP, Haendeler J, Zeiher AM, Dimmeler S. Cell-to-cell connection of endothelial progenitor cells with cardiac myocytes by nanotubes: a novel mechanism for cell fate changes? Circ Res 2005; 96(10): 1039-41.
130. Gruh I, Beilner J, Blomer U, et al. No evidence of transdifferentiation of human endothelial progenitor cells into cardiomyocytes after coculture with neonatal rat cardiomyocytes. Circulation 2006; 113(10): 1326-34.
131. Gerdes HH, Bukoreshtliev NV, Barroso JF. Tunneling nanotubes: a new route for the exchange of components between animal cells. FEBS Lett 2007; 581(11): 2194-201.
132. Gerdes HH, Carvalho RN. Intercellular transfer mediated by tunneling nanotubes. Curr Opin Cell Biol 2008; 20(4): 470-5.
133. Gurke S, Barroso JF, Gerdes HH. The art of cellular communication: tunneling nanotubes bridge the divide. Histochem Cell Biol 2008; 129(5): 539-50.
134. Gurke S, Barroso JF, Hodneland E, Bukoreshtliev NV, Schlicker O, Gerdes HH. Tunneling nanotube (TNT)-like structures facilitate a constitutive, actomyosin-dependent exchange of endocytic organelles between normal rat kidney cells. Exp Cell Res 2008; 314(20): 3669-83.
135. Gwak SJ, Bhang SH, Yang HS, et al. In vitro cardiomyogenic differentiation of adipose-derived stromal cells using transforming growth factor-beta1. Cell Biochem Funct 2009; 27(3): 148-54.
136. Karra R, Wu SM. Multipotent stem cells in cardiac regenerative therapy. Regen Med 2008; 3(2): 189-98.
137. Beguin PC, El-Helou V, Assimakopoulos J, et al. The phenotype and potential origin of nestin(+) cardiac myocyte-like cells following infarction. J Appl Physiol 2009; 107(4): 1241-8.
138. Padin-Iruegas ME, Misao Y, Davis ME, et al. Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation 2009; 120(10): 876-87.
139. Stamm C, Choi YH, Nasseri B, Hetzer R. A heart full of stem cells: the spectrum of myocardial progenitor cells in the postnatal heart. Ther Adv Cardiovasc Dis 2009; 3(3): 215-29.
140. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009; 324(5923): 98-102.
141. Hayashi S, Inoue A. Cardiomyocytes re-enter the cell cycle and contribute to heart development after differentiation from cardiac progenitors expressing Isl1 in chick embryo. Dev Growth Differ 2007; 49(3): 229-39.
142. Omatsu-Kanbe M, Matsuura H. A novel type of self-beating cardiomyocytes in adult mouse ventricles. Biochem Biophys Res Commun 2009; 381(3): 361-6.
143. Yanagi K, Takano M, Narazaki G, et al. Hyperpolarizationactivated cyclic nucleotide-gated channels and T-type calcium channels confer automaticity of embryonic stem cell-derived cardiomyocytes. Stem Cells 2007; 25(11): 2712-9.
144. Yang L, Soonpaa MH, Adler ED, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cellderived population. Nature 2008; 453(7194): 524-8.
145. Wu SM, Fujiwara Y, Cibulsky SM, et al. Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the mammalian heart. Cell 2006; 127(6): 1137-50.
146. Wu SM, Chien KR, Mummery C. Origins and fates of cardiovascular progenitor cells. Cell 2008; 132(4): 537-43.
147. Christoffels VM, Mommersteeg MT, Trowe MO, et al. Formation of the venous pole of the heart from an Nkx2-5-negative precursor population requires Tbx18. Circ Res 2006; 98(12): 1555-63.
148. Prall OW, Menon MK, Solloway MJ, et al. An Nkx2-5/Bmp2/Smad1 negative feedback loop controls heart progenitor specification and proliferation. Cell 2007; 128(5): 947-59.
149. Aghila Rani KG, Jayakumar K, Srinivas G, Nair RR, Kartha CC. Isolation of ckit-positive cardiosphere-forming cells from human atrial biopsy. Asian Cardiovasc Thorac Ann 2008; 16(1): 50-6.
150. Chamuleau SA, Vrijsen KR, Rokosh DG, Tang XL, Piek JJ, Bolli R. Cell therapy for ischaemic heart disease: focus on the role of resident cardiac stem cells. Neth Heart J 2009; 17(5): 199-207.
151. Li Z, Lee A, Huang M, et al. Imaging survival and function of transplanted cardiac resident stem cells. J Am Coll Cardiol 2009; 53(14): 1229-40.
152. Scobioala S, Klocke R, Kuhlmann M, et al. Up-regulation of nestin in the infarcted myocardium potentially indicates differentiation of resident cardiac stem cells into various lineages including cardiomyocytes. Faseb J 2008; 22(4): 1021-31.
153. Tallini YN, Greene KS, Craven M, et al. c-kit expression identifies cardiovascular precursors in the neonatal heart. Proc Natl Acad Sci USA 2009; 106(6): 1808-13.
154. Torella D, Ellison GM, Mendez-Ferrer S, Ibanez B, Nadal-Ginard B. Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential for myocardial regeneration. Nat Clin Pract Cardiovasc Med 2006; 3(Suppl 1): S8-13.
155. Yu XY, Geng YJ, Li XH, et al. The effects of mesenchymal stem cells on c-kit up-regulation and cell-cycle re-entry of neonatal cardiomyocytes are mediated by activation of insulin-like growth factor 1 receptor. Mol Cell Biochem 2009; 332(1-2): 25-32.
156. Cebotari S, Mertsching H, Kallenbach K, et al. Construction of autologous human heart valves based on an acellular allograft matrix. Circulation 2002; 106(12 Suppl 1): I63-I8.
157. Eitan Y, Sarig U, Dahan N, Machluf M. Acellular cardiac extracellular matrix as a scaffold for tissue engineering: In-vitro cell support, remodeling and biocompatibility. Tissue Eng Part C Methods 2010; 16(4): 671-83.
158. Elder BD, Eleswarapu SV, Athanasiou KA. Extraction techniques for the decellularization of tissue engineered articular cartilage constructs. Biomaterials 2009; 30(22): 3749-56.
159. Iop L, Renier V, Naso F, et al. The influence of heart valve leaflet matrix characteristics on the interaction between human mesenchymal stem cells and decellularized scaffolds. Biomaterials 2009; 30(25): 4104-16.
160. Knight RL, Wilcox HE, Korossis SA, Fisher J, Ingham E. The use of acellular matrices for the tissue engineering of cardiac valves. Proc Inst Mech Eng H 2008; 222(1): 129-43.
161. Mirsadraee S, Wilcox HE, Watterson KG, et al. Biocompatibility of acellular human pericardium. J Surg Res 2007; 143(2): 407-14.
162. Schmidt CE, Baier JM. Acellular vascular tissues: natural biomaterials for tissue repair and tissue engineering. Biomaterials 2000; 21(22): 2215-31.
163. Tedder ME, Liao J, Weed B, et al. Stabilized collagen scaffolds for heart valve tissue engineering. Tissue Eng Part A 2009; 15(6): 1257-68.
164. Tudorache I, Cebotari S, Sturz G, et al. Tissue engineering of heart valves: biomechanical and morphological properties of decellularized heart valves. J Heart Valve Dis 2007; 16(5): 567-73; discussion 74.
165. Wainwright JM, Czajka CA, Patel UB, et al. Preparation of Cardiac Extracellular Matrix from an Intact Porcine Heart. Tissue Eng Part C Methods 2010; 16(3): 525-32.
166. Yang M, Chen CZ, Wang XN, Zhu YB, Gu YJ. Favorable effects of the detergent and enzyme extraction method for preparing decellularized bovine pericardium scaffold for tissue engineered heart valves. J Biomed Mater Res B Appl Biomater 2009; 91(1): 354-61.
167. Ye X, Zhao Q, Sun X, Li H. Enhancement of mesenchymal stem cell attachment to decellularized porcine aortic valve scaffold by in vitro coating with antibody against CD90: a preliminary study on antibody-modified tissue-engineered heart valve. Tissue Eng Part A 2009; 15(1): 1-11.
168. Jo J, Nagaya N, Miyahara Y, et al. Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction: benefit of a novel nonviral vector, cationized dextran. Tissue Eng 2007; 13(2): 313-22.
169. Stock UA, Schenke-Layland K. Performance of decellularized xenogeneic tissue in heart valve replacement. Biomaterials 2006; 27(1): 1-2.
170. Rieder E, Kasimir MT, Silberhumer G, et al. Decellularization protocols of porcine heart valves differ importantly in efficiency of cell removal and susceptibility of the matrix to recellularization with human vascular cells. J Thorac Cardiovasc Surg 2004; 127(2): 399-405.
171. Schenke-Layland K, Vasilevski O, Opitz F, et al. Impact of decellularization of xenogeneic tissue on extracellular matrix integrity for tissue engineering of heart valves. J Struct Biol 2003; 143(3): 201-8.
172. Schenke-Layland K, Opitz F, Gross M, et al. Complete dynamic repopulation of decellularized heart valves by application of defined physical signals-an in vitro study. Cardiovasc Res 2003; 60(3): 497-509.
173. Ott HC, Matthiesen TS, Brechtken J, et al. The adult human heart as a source for stem cells: repair strategies with embryonic-like progenitor cells. Nat Clin Pract Cardiovasc Med 2007; 4 Suppl 1: S27-39.
174. Ott HC, Matthiesen TS, Goh SK, et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med 2008; 14(2): 213-21.
175. Forte G, Carotenuto F, Pagliari F, et al. Criticality of the biological and physical stimuli array inducing resident cardiac stem cell determination. Stem Cells 2008; 26(8): 2093-103.
176. Niebruegge S, Bauwens CL, Peerani R, et al. Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor. Biotechnol Bioeng 2009; 102(2): 493-507.
177. Li SC, Loudon WG. A novel and generalizable organotypic slice platform to evaluate stem cell potential for targeting pediatric brain tumors. Cancer Cell Int 2008; 8: 9.